Načítá se...
Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial
BACKGROUND: The results of the Trial Assigning IndividuaLized Options for Treatment (TAILORx) suggested that approximately 70% of T1-2N0M0, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients can avoid chemotherapy and receive only adjuvant endo...
Uloženo v:
Vydáno v: | Chin Med J (Engl) |
---|---|
Hlavní autoři: | , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
Wolters Kluwer Health
2019
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6964955/ https://ncbi.nlm.nih.gov/pubmed/31809316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000000548 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|